Genetic Technologies Ltd (GENE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genetic Technologies Ltd (GENE) has a cash flow conversion efficiency ratio of -3.096x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.67 Million) by net assets ($1.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GENE net asset quality index to measure how much of total assets are equity-financed.
Genetic Technologies Ltd - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Genetic Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GENE operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Genetic Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genetic Technologies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
-0.039x |
|
FEEDBACK PLC LS-5
F:GZM0
|
N/A |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
-0.010x |
|
Hiremii Ltd
AU:HMI
|
-0.436x |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
-0.091x |
|
ATI Physical Therapy Inc
NYSE:ATIP
|
-0.071x |
|
HB Stockholdings Limited
NSE:HBSL
|
-0.126x |
|
Judges Scientific Plc
LSE:JDG
|
0.204x |
Annual Cash Flow Conversion Efficiency for Genetic Technologies Ltd (2000–2024)
The table below shows the annual cash flow conversion efficiency of Genetic Technologies Ltd from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see Genetic Technologies Ltd (GENE) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $1.83 Million | $-9.68 Million | -5.288x | -507.08% |
| 2023-06-30 | $11.16 Million | $-9.72 Million | -0.871x | -152.89% |
| 2022-06-30 | $16.43 Million | $-5.66 Million | -0.344x | -17.80% |
| 2021-06-30 | $21.53 Million | $-6.30 Million | -0.292x | +28.38% |
| 2020-06-30 | $13.99 Million | $-5.71 Million | -0.408x | +88.09% |
| 2019-06-30 | $1.77 Million | $-6.07 Million | -3.429x | -186.63% |
| 2018-06-30 | $4.71 Million | $-5.64 Million | -1.196x | -85.73% |
| 2017-06-30 | $10.58 Million | $-6.81 Million | -0.644x | +0.95% |
| 2016-06-30 | $11.88 Million | $-7.73 Million | -0.650x | -27.20% |
| 2015-06-30 | $18.96 Million | $-9.69 Million | -0.511x | +91.50% |
| 2014-06-30 | $1.83 Million | $-10.99 Million | -6.012x | -360.56% |
| 2013-06-30 | $5.76 Million | $-7.52 Million | -1.305x | -144.99% |
| 2012-06-30 | $14.40 Million | $-7.67 Million | -0.533x | -262.57% |
| 2011-06-30 | $6.81 Million | $2.23 Million | 0.328x | +143.55% |
| 2010-06-30 | $5.72 Million | $-4.30 Million | -0.753x | -115.70% |
| 2009-06-30 | $17.49 Million | $-6.10 Million | -0.349x | -1815.27% |
| 2008-06-30 | $20.83 Million | $423.68K | 0.020x | -84.38% |
| 2007-06-30 | $16.90 Million | $2.20 Million | 0.130x | +138.82% |
| 2006-06-30 | $18.27 Million | $-6.13 Million | -0.335x | -15.98% |
| 2005-06-30 | $22.75 Million | $-6.58 Million | -0.289x | -9.13% |
| 2004-06-30 | $17.07 Million | $-4.52 Million | -0.265x | -627.25% |
| 2003-06-30 | $27.28 Million | $-993.71K | -0.036x | +65.80% |
| 2002-06-30 | $31.14 Million | $-3.32 Million | -0.107x | -81.95% |
| 2001-06-30 | $38.07 Million | $-2.23 Million | -0.059x | -39.21% |
| 2000-06-30 | $7.58 Million | $-318.68K | -0.042x | -- |
About Genetic Technologies Ltd
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more